211 related articles for article (PubMed ID: 35879762)
21. PCGF1 is a prognostic biomarker and correlates with tumor immunity in gliomas.
Xie J; Qiao L; Deng G; Liang N; Xing L; Zhang J
Ann Transl Med; 2022 Feb; 10(4):227. PubMed ID: 35280367
[TBL] [Abstract][Full Text] [Related]
22. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
[TBL] [Abstract][Full Text] [Related]
23. Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.
Shu C; Wang Q; Yan X; Wang J
J Mol Neurosci; 2018 Apr; 64(4):491-500. PubMed ID: 29502292
[TBL] [Abstract][Full Text] [Related]
24. High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.
Zhang F; Cai HB; Liu HZ; Gao S; Wang B; Hu YC; Cheng HW; Liu JX; Gao Y; Hong WM
Dis Markers; 2022; 2022():8133505. PubMed ID: 35493303
[TBL] [Abstract][Full Text] [Related]
25. MAPK-activated protein kinase 2 is associated with poor prognosis of glioma patients and immune inhibition in glioma.
Sun J; Wu S; Zhao W; Xue S; Zhang L; Ren J
Front Oncol; 2024; 14():1307992. PubMed ID: 38322416
[TBL] [Abstract][Full Text] [Related]
26. CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses.
Lou H; Wu Z; Wei G
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186304
[TBL] [Abstract][Full Text] [Related]
27. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
28. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
Yang G; Tang S; Zhang J; Qin L
World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progression.
Chen X; Jiang X; Wang H; Wang C; Wang C; Pan C; Zhou F; Tian J; Niu X; Nie Z; Chen W; Huang X; Pu J; Li C
Aging (Albany NY); 2022 Jun; 14(12):5211-5222. PubMed ID: 35771139
[TBL] [Abstract][Full Text] [Related]
30. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
31. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
[TBL] [Abstract][Full Text] [Related]
32. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
Zhang W; Zhang L; Dong H; Peng H
Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
[TBL] [Abstract][Full Text] [Related]
33. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
34. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
Mou Y; Zhang L; Liu Z; Song X
BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
[TBL] [Abstract][Full Text] [Related]
35. Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.
Chen Y; Wang Y; He Q; Wang W; Zhang T; Wang Z; Dong J; Lan Q; Zhao J
Cancer Med; 2021 Jul; 10(13):4644-4657. PubMed ID: 34121368
[TBL] [Abstract][Full Text] [Related]
36. NCAPD3 is a prognostic biomarker and is correlated with immune infiltrates in glioma.
Qu L; Che H; Zhao J; Lu X; Ren Z; Wu Y; Liu Q; Guan H
Histol Histopathol; 2024 Mar; ():18736. PubMed ID: 38576381
[TBL] [Abstract][Full Text] [Related]
37. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
[TBL] [Abstract][Full Text] [Related]
38. LMO1 Plays an Oncogenic Role in Human Glioma Associated With NF-kB Pathway.
Gao L; Wu J; Wang H; Yang Y; Zheng Z; Ni B; Wang X; Peng Y; Li Y
Front Oncol; 2022; 12():770299. PubMed ID: 35280742
[TBL] [Abstract][Full Text] [Related]
39. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
[No Abstract] [Full Text] [Related]
40. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma.
Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z
Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
